Unjha Formulations P/E Ratio
Current P/E Ratio
31.43
High Valuation
Very High - High growth expectations or significantly overvalued
Unjha Formulations P/E ratio. Unjha Formulations (UNJHAFOR) P/E ratio is 31.43 (High), EPS (TTM) ₹1.57, current price ₹32.00 on BSE — Very High - High growth expectations or significantly overvalued. Check UNJHAFOR company valuation to track the company's total market size over time.
Current Valuation Metrics
P/E Ratio
31.43
Current Price
₹32.00
EPS (TTM)
₹1.57
Exchange
BSE
Valuation Signal
Signal
Overvalued
Sector Context
Sector Average
56.39
Sector Median
32.41
Sector Rank
#11 of 199
Sector Percentile
5.5%
UNJHAFOR P/E Ratio — Valuation Signal & Historical Context
Unjha Formulations P/E 31.43 — signal: Overvalued. For live price, revenue and the complete fundamental profile, see Unjha Formulations stock price NSE.
- Stock appears overvalued with PE of 31.43, suggesting caution for new investments
- Trading at discount to sector average PE of 56.39
UNJHAFOR vs Healthcare Peers — P/E Ratio Comparison
Unjha Formulations P/E 31.43 vs Healthcare average 56.39, median 32.41 — range 2.04–740.29.
Sector Average
56.39
Sector Median
32.41
Lowest P/E
2.04
Highest P/E
740.29
Companies
199
| Company | Symbol | P/E Ratio | Market Cap (₹ Cr) | Valuation |
|---|---|---|---|---|
| Sunrest Lifescience | SUNREST | 2.04 | ₹65 | Low |
| Murae Organisor | MURAE | 2.86 | ₹41 | Low |
| Phaarmasia | PHRMASI | 3.41 | ₹63 | Low |
| Sun Pharma Advanced Rese… | SPARC | 3.98 | ₹6,206 | Low |
| Dipna Pharmachem | DPL | 4.57 | ₹12 | Low |
| JFL Life Sciences | JFLLIFE | 4.88 | ₹66 | Low |
| GKB Ophthalmics | GKB | 5.88 | ₹32 | Low |
| Kabra Drugs | KABRADG | 6.09 | ₹44 | Low |
| Royal Sense | ROYAL | 6.58 | ₹47 | Low |
| Colinz Laboratories | COLINZ | 6.62 | ₹18 | Low |